ORIC / ORIC Pharmaceuticals, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatme

Exhibit 99.1 ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top-tier healthcare specialist investors acros

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 ORIC Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

ORIC Pharmaceuticals, Inc. 19,230,845 Shares of Common Stock

424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-287949 PROSPECTUS ORIC Pharmaceuticals, Inc. 19,230,845 Shares of Common Stock This prospectus relates to the offer and resale from time to time of up to 19,230,845 shares of our common stock, par value $0.0001 per share (the “Shares”), by the selling stockholders identified in this prospectus, including their transferee

ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080

CORRESP ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 June 17, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-287949 Acceleration Request Requested Date: June 20, 2025 R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 11, 2025 ORIC Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 11, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

As filed with the Securities and Exchange Commission on June 11, 2025

Table of Contents As filed with the Securities and Exchange Commission on June 11, 2025 Registration No.

Filing Fee Table

EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) ORIC Pharmaceuticals, Inc.

Securities Purchase Agreement, dated May 23, 2025

Exhibit 10.1 ORIC PHARMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of May 23, 2025 (the “Effective Date”), by and among ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Purchasers”

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC Broad and deep PSA responses achieved, w

Exhibit 99.2 ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all co

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterpri

Exhibit 99.1 ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital Pro forma cash and investments expected to fund current operating plan in

Form of Pre-Funded Warrant

Exhibit 4.1 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (i) S

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented p

Exhibit 99.1 ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

As filed with the Securities and Exchange Commission on March 20, 2025

As filed with the Securities and Exchange Commission on March 20, 2025 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ORIC Pharmaceuticals, Inc.

Amended and Restated 2022 Inducement Equity Incentive Plan, and form agreements thereunder.

Exhibit 10.1 ORIC PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 ORIC Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39269 47-1787157 (State or Other Jurisdiction of Incorporation) (Commissi

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on

Exhibit 99.1 ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase 3 trial in mCRPC expected in 1H

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commis

Amended and Restated Outside Director Compensation Policy

Exhibit 10.10 ORIC PHARMACEUTICALS, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Originally effective as of April 23, 2020, as amended by the Board of Directors through December 12, 2024. ORIC Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”)

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEU

Insider Trading Policy, as amended

Exhibit 19.1 ORIC PHARMACEUTICALS, INC. INSIDER TRADING POLICY (As amended through February 10, 2025) A. POLICY OVERVIEW ORIC Pharmaceuticals, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibito

Exhibit 99.1 ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in c

Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding

Exhibit 99.1 Company Overview January 2025 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us” or “our”) future financial condition, results of operatio

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss

ORIC / ORIC Pharmaceuticals, Inc. / Nextech Crossover I GP S.a r.l. - SC 13G/A Passive Investment

SC 13G/A 1 tm2427660d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statem

ORIC / ORIC Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment

SC 13G/A 1 oric13ga5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the app

ORIC / ORIC Pharmaceuticals, Inc. / COLUMN GROUP II, LP - SC 13G/A Passive Investment

SC 13G/A 1 d851421dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68622P109 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement

ORIC / ORIC Pharmaceuticals, Inc. / ALKEON CAPITAL MANAGEMENT LLC - ORIC PHARMACEUTICALS, INC. Passive Investment

SC 13G/A 1 p24-3281sc13ga.htm ORIC PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Oric Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this sta

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commi

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at

Exhibit 99.1 ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced clinical collaborations with multiple strategic partners to support ongoing trial evaluating ORIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered i

Exhibit 99.1 ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to support the ongoing Phase 1b trial of ORIC-944

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

Amendment No.1 to the License and Collaboration Agreement between the Registrant and Voronoi Inc., effective March 20, 2024

Exhibit 10.1 AMENDMENT NO. 1 TO THE LICENSE AND COLLABORATION AGREEMENT THIS AMENDMENT NO. 1 TO THE LICENSE AND COLLABORATION AGREEMENT (this “Amendment No. 1”), effective March 20, 2024 (the “Amendment No. 1 Effective Date”), is entered into by and between Voronoi Inc., a limited corporation duly established under the Republic of Korea’s commercial code, having offices at S. 18th F, Songdogwahak-

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated P

Exhibit 99.1 ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best-in-clas

Amended and Restated Outside Director Compensation Policy

Exhibit 10.2 ORIC PHARMACEUTICALS, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Originally effective as of April 23, 2020, as amended by the Board of Directors through March 26, 2024. ORIC Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) repr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Amended and Restated 2022 Inducement Equity Incentive Plan, and form agreements thereunder

Exhibit 10.1 ORIC PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permi

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ORIC Pharmaceuticals, Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 ORIC Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39269 47-1787157 (State or Other Jurisdiction of Incorporation) (Commissi

As filed with the Securities and Exchange Commission on March 29, 2024

As filed with the Securities and Exchange Commission on March 29, 2024 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi

Compensation Recovery Policy

Exhibit 97.1 ORIC PHARMACEUTICALS, INC. COMPENSATION RECOVERY POLICY As adopted on September 14, 2023 ORIC Pharmaceuticals, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’

Form of Indenture

Exhibit 4.2 ORIC PHARMACEUTICALS, INC. INDENTURE Dated as of [, 20] [], as Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establis

Registration Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritize

Exhibit 99.1 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies Initiation of combination study of ORIC-944 with AR inhibitor(s) in metastatic p

As filed with the Securities and Exchange Commission on March 11, 2024

Table of Contents As filed with the Securities and Exchange Commission on March 11, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEU

ORIC / ORIC Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment

SC 13G/A 1 oric13ga4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appr

ORIC / ORIC Pharmaceuticals, Inc. / ALKEON CAPITAL MANAGEMENT LLC Passive Investment

SC 13G/A 1 oric13ga2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Oric Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the a

ORIC / ORIC Pharmaceuticals, Inc. / Prosight Management, LP - SC 13G/A Passive Investment

SC 13G/A 1 d723724dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement)

ORIC / ORIC Pharmaceuticals, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

SC 13G/A 1 ORICSC13GA.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ORIC PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 68622P109 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the app

ORIC / ORIC Pharmaceuticals, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 68622P109 (CUSIP Number) January 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t

ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080

ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 January 31, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549  Attention: Tim Buchmiller, Staff Attorney Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-276719 Acceleration Request Requested Date: 

ORIC / ORIC Pharmaceuticals, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G Passive Investment

SC 13G 1 ef20020178sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Sec

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) ORIC Pharmaceuticals, Inc.

As filed with the Securities and Exchange Commission on January 26, 2024

Table of Contents As filed with the Securities and Exchange Commission on January 26, 2024 Registration No.

AGREEMENT

EX-99.A 2 d709301dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of ORIC Pharmaceuticals, Inc. Date: January 25, 2024 FRAZIER LIFE SCIENCES PUBLI

ORIC / ORIC Pharmaceuticals, Inc. / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment

SC 13G 1 d709301dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.  )* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P109 (CUSIP Number) January 23, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New Enterprise Associate

EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Announces $125 Million Private Placement Financing Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), and Nextech Pro forma cash and investments expected to fund current operating plan into late 2026 SOUTH SAN FRANCISCO an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 20, 2024 ORIC Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 20, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss

Securities Purchase Agreement, dated January 20, 2024

EX-10.1 Exhibit 10.1 ORIC PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (the “Agreement”) is made as of January 20, 2024 (the “Effective Date”), by and among ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Purchaser

Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding

Exhibit 99.1 Company Overview January 2024 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us” or “our”) future financial condition, results of operatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2024 ORIC Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi

ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080

ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 December 26, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Sprague Hamill, Senior Counsel Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-276077 Acceleration Request Requested

Filing Fee Table

CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) ORIC Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees

As filed with the Securities and Exchange Commission on December 15, 2023

S-3 Table of Contents As filed with the Securities and Exchange Commission on December 15, 2023 Registration No.

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development Preliminary evidence of clinical antimyeloma activity,

Exhibit 99.1 Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adv

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commis

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commis

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile Initial Phase 1b

Exhibit 99.1 ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile Initial Phase 1b data for ORIC-533 in patients with multiple myeloma to be presented at the 65th ASH Annual Meeting being held December 9-12, 2023 Initia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response

EX-99.1 Exhibit 99.1 Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dos

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 21, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2023 ORIC Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi

ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates Initial Phase 1b clinical data for ORIC-114 in EGFR/HER2-mutated cancers to be presented at the ESMO Congress being held October 20-24, 2023 Initial Phase 1b c

Exhibit 99.1 ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates Initial Phase 1b clinical data for ORIC-114 in EGFR/HER2-mutated cancers to be presented at the ESMO Congress being held October 20-24, 2023 Initial Phase 1b clinical data expected for ORIC-533 in multiple myeloma in fourth quarter of 2023 and ORIC-944 in prostate cancer in first quarter of 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

ORIC / ORIC Pharmaceuticals Inc / Nextech Crossover I GP S.a r.l. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) June 27, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

Securities Purchase Agreement, dated June 24, 2023

EX-10.1 Exhibit 10.1 ORIC PHARMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of June 24, 2023 (the “Effective Date”), by and among ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Pu

ORIC Pharmaceuticals Announces $85 Million Private Placement Financing

EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Announces $85 Million Private Placement Financing June 26, 2023 Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital Pro forma cash and investments expected to fund current operating plan into late 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 26, 2023 (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2023 ORIC Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

Form of Pre-Funded Warrant

EX-4.1 Exhibit 4.1 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLES

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

JOINT FILING AGREEMENT June 9, 2023

EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT June 9, 2023 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (includin

ORIC / ORIC Pharmaceuticals Inc / Prosight Management, LP - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68622P109 (CUSIP Number) May 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, an

Exhibit 99.1 ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Preclinical data for ORIC-944 and PLK4 program presented at the 2023 AACR Annual Meeting Cash and investmen

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

DEF 14A 1 d447451ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 20, 2023 ORIC Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 20, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissio

Amended and Restated Bylaws

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ORIC PHARMACEUTICALS, INC. (as amended and restated on March 20, 2023) TABLE OF CONTENTS Page ARTICLE I—CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II—MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDERS’ MEETINGS 9 2.6 QU

As filed with the Securities and Exchange Commission on March 16, 2023

S-8 As filed with the Securities and Exchange Commission on March 16, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2023 ORIC Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissio

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ORIC Pharmaceuticals, Inc.

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEU

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-muta

Exhibit 99.1 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Received $25 million equity investment from Pfizer, and entered into clinical development co

ORIC / ORIC Pharmaceuticals Inc / ALKEON CAPITAL MANAGEMENT LLC Passive Investment

SC 13G/A 1 oric13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Oric Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the approp

ORIC / ORIC Pharmaceuticals Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

ORIC / ORIC Pharmaceuticals Inc / VICTORY CAPITAL MANAGEMENT INC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No.1)* Oric Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

ORIC / ORIC Pharmaceuticals Inc / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ORIC PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 68622P109 (CUSIP Number) JANUARY 13, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and OR

EX-99.1 2 d448025dex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Development candidate selected for PLK4 synthetic lethal breast cancer prog

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2023 ORIC Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi

ORIC / ORIC Pharmaceuticals Inc / PFIZER INC - SC 13G ORIC PHARMACEUTICALS Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 23, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

ORIC / ORIC Pharmaceuticals Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P 109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-

JOINT FILING AGREEMENT

EX-99.1 2 ss1628562ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated December 22, 2022, with respect to the common stock of ORIC Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each o

SECURITIES PURCHASE AGREEMENT

EX-99.2 Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 21, 2022, between ORIC Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Pfizer Inc., a corporation organized under the laws of the State of Delaware (the “Purchaser”). WHEREAS, subject to the terms and conditions

5,376,344 Shares of Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255833 PROSPECTUS SUPPLEMENT (To Prospectus dated April 27, 2022) 5,376,344 Shares of Common Stock We are offering 5,376,344 shares of our common stock directly to the investor, Pfizer Inc., in this offering at a price per share of $4.65. This offering is being made without an underwriter or a placement agent and we are

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer ORIC and Pfizer have entered into a clinical development collaboration for a Phase 2

EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer ORIC and Pfizer have entered into a clinical development collaboration for a Phase 2 study of ORIC-533 in combination with elranatamab in multiple myeloma Jeff Settleman, Ph.D., Chief Scientific Officer, Pfizer On

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 21, 2022 ORIC Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 21, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commis

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss

ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update Initial Phase 1b data for three ongoing clinical studies expected to be reported in 1H 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers,

Exhibit 99.1 ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update Initial Phase 1b data for three ongoing clinical studies expected to be reported in 1H 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Ongoing clinical development of ORIC-114 expanded with FDA clearance of US IND Preclinical data on ORIC-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi

ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to repor

Exhibit 99.1 ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H 2023 Cash and investments of $237.8 million expected to fund current operating plan into 2H 2024 SOUTH SAN FRANCISCO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ORIC PHARMACEUTICALS, INC. (Name of Subject Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ORIC PHARMACEUTICALS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.0001 par value (Title of Class of Securities) 68622P109 (CUSIP Number of

Form of Reminder Email.

Exhibit (a)(1)(E) Form of Reminder Email The ORIC Pharmaceuticals, Inc. (?ORIC?) offer to exchange certain outstanding stock options for new stock options (referred to as the ?Offer?) currently is still open. Please note that the Offer will expire at 9:00 p.m., Pacific Time, on July 20, 2022, unless we extend the Offer. The Offer deadline will be strictly enforced, so we encourage you to give your

Form of Notice Email to Eligible Employees Regarding Expiration of Offering Period.

Exhibit (a)(1)(F) Form of Notice Email to Eligible Employees Regarding Expiration of Offering Period From: Jacob M.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ORIC PHARMACEUTICALS, INC. (Name of Subject Company (Issuer) and Filing Person (Off

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ORIC PHARMACEUTICALS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.0001 par value (Title of Class of Securities) 68622P109 (CUSIP Number of Class of Securities? Underlying C

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 17, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

Email to All Eligible Employees.

Exhibit (a)(1)(B) Email to All Eligible Employees From: Jacob M. Chacko, M.D., President and Chief Executive Officer, ORIC Pharmaceuticals, Inc. To: All Eligible Employees Date: June 21, 2022 Subject: LAUNCH OF ORIC?S STOCK OPTION EXCHANGE PROGRAM Dear ORIC Eligible Employee: You are receiving this email because you are eligible to participate in a voluntary, one-time stock option exchange offer (

Election Terms and Conditions.

Exhibit (a)(1)(C) ORIC PHARMACEUTICALS, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS ELECTION TERMS AND CONDITIONS 1. I agree that my decision to accept or reject the Offer with respect to some or all of my eligible option grants is entirely voluntary and is subject to the terms and conditions of the Offer. 2. I understand that I may change my election at any time

Form of Confirmation to Eligible Employees.

Exhibit (a)(1)(D) Form of Confirmation to Eligible Employees ORIC Pharmaceuticals, Inc.

Employee Presentation.

Stock Option Exchange June 22, 2022 Exhibit (a)(1)(G) Stock Option Exchange Overview What are we doing and why? Options are a key component of our incentive and retention program, and we have offered them broadly, at all employee levels, since ORIC?s founding We believe options encourage employees to act like owners of the business by: Motivating us to work toward our collective success Rewarding

Email to Investors

Exhibit (a)(5) From: Dominic Piscitelli, CFO To: Certain Investors Subject: ORIC Employee Stock Option Exchange As you may have seen, today we filed a tender offer related to a voluntary stock option exchange for our employees.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form TO-I (Form Type) ORIC Pharmaceuticals, Inc.

Screenshots from Offer Website.

Exhibit (a)(1)(H)

Offer to Exchange Certain Outstanding Stock Options for New Stock Options, dated June 21, 2022.

Table of Contents Exhibit (a)(1)(A) ORIC PHARMACEUTICALS, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS This document constitutes part of the prospectus relating to the securities that have been registered under the Securities Act of 1933, as amended. The prospectus relates to the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan and the ORIC Pharmaceuticals, I

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

License and Collaboration Agreement between the registrant and Voronoi, Inc., dated as of October 19, 2020.

Exhibit 10.3 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [***]. LICENSE AND COLLABORATION AGREEMENT BETWEEN ORIC PHARMACEUTICALS, INC. AND VORONOI INC. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 3 ARTICLE II GRANT OF LICENSE 14 ARTICLE III GOVER

ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report

Exhibit 99.1 ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H2023 Four preclinical presentations at the 2022 AACR Annual Meeting Cash and investments of $256.2 million expected to

License Agreement between the registrant and Mirati Therapeutics, Inc., dated as of August 3, 2020.

Exhibit 10.2 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [***]. LICENSE AGREEMENT THIS LICENSE AGREEMENT (this ?Agreement?), entered into as of August 3, 2020 (the ?Effective Date?), is entered into by and between Mirati Therapeutics, Inc., a Dela

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

Filing Fee Disclosure and Payment Methods

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ORIC Pharmaceuticals, Inc.

As filed with the Securities and Exchange Commission on March 22, 2022

As filed with the Securities and Exchange Commission on March 22, 2022 Registration No.

As filed with the Securities and Exchange Commission on March 22, 2022.

Table of Contents As filed with the Securities and Exchange Commission on March 22, 2022.

Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding

Fourth Quarter and Full Year 2021 Financial Results and Operational Update March 21, 2022 Exhibit 99.

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Announces decision to discontinue development of ORIC-101 Company will focus on advancing its three single agent Phase 1 programs, ORIC-533 in mul

Exhibit 99.1 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Announces decision to discontinue development of ORIC-101 Company will focus on advancing its three single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, with initial data expected from the three programs in 1H 2

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissio

Registration Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) ORIC Pharmaceuticals, Inc.

Description of the Registrant’s securities

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S CAPITAL STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and the

Amended and Restated Outside Director Compensation Policy

Exhibit 10.10 ORIC PHARMACEUTICALS, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Originally effective as of April 23, 2020, as amended by the Board of Directors as of March 16, 2022 (the ?Effective Date?). ORIC Pharmaceuticals, Inc. (the ?Company?) believes that providing cash and equity compensation to its members of the Board of Directors (the ?Board,? and members of the Board,

Power of Attorney

Table of Contents As filed with the Securities and Exchange Commission on March 21, 2022.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEU

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissio

2022 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements.

Exhibit 10.1 ORIC PHARMACEUTICALS, INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonst

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 ORIC Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39269 47-1787157 (State or Other Jurisdiction of Incorporation) (Commissio

ORIC / ORIC Pharmaceuticals Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

ORIC / ORIC Pharmaceuticals Inc / COLUMN GROUP II, LP - SC 13G/A Passive Investment

SC 13G/A 1 d314465dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement)

ORIC / ORIC Pharmaceuticals Inc / VICTORY CAPITAL MANAGEMENT INC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No.)* Oric Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones ORIC-101 program on track for updates from both ongoing clinical trials in first half of 2022 Initial Phase 1b data from ORIC-533 in multiple myeloma, ORIC-114 in E

Exhibit 99.1 ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones ORIC-101 program on track for updates from both ongoing clinical trials in first half of 2022 Initial Phase 1b data from ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers and ORIC-944 in prostate cancer expected in first half of 2023 Cash and investments of $280.8 million expected to fund o

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 10, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss

ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors

Exhibit 99.1 ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors SOUTH SAN FRANCISCO and SAN DIEGO, CA ? November 10, 2021 ? ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You curr

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

2020 Employee Stock Purchase Plan, and form agreements thereunder

Exhibit 10.2 ORIC PHARMACEUTICALS, Inc. 2020 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an ?employee stock purchase plan? under Se

ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update Initial clinical data from Phase 1b trial of ORIC-101 in combination with enzalutamide and preclinical data on ORIC-114 presented at AACR-NCI-EORTC Update on ora

Exhibit 99.1 ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update Initial clinical data from Phase 1b trial of ORIC-101 in combination with enzalutamide and preclinical data on ORIC-114 presented at AACR-NCI-EORTC Update on oral CD73 inhibitor program to be presented at the American Society of Hematology (ASH) Annual Meeting and Phase 1 trial initiation of singl

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 7, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi

ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was

EX-99.1 2 d181647dex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agent enzalutamide ORIC-101 plasma co

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 17, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi

First Amendment to Lease between the Registrant and Britannia Pointe Grand Limited Partnership, dated August 12, 2021

Exhibit 10.1 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (?First Amendment?) is made and entered into as of August 12, 2021, by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership (?Landlord?), and ORIC PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). R E C I T A L S : A. Landlord and Tenant are parties to the Lease dated June 5, 2015 (the ?Le

ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors

EX-99.1 3 d127312dex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors SOUTH SAN FRANCISCO and SAN DIEGO, CA – August 16, 2021 – ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of 25-year industry vetera

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 12, 2021, with respect to the ordinary shares of ORIC Pharmaceuticals, Inc.

ORIC / ORIC Pharmaceuticals Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P 109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi

ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update ORIC-101 on track for initial Phase 1b data readout in prostate cancer in 2H21 ORIC-533 IND cleared by FDA; initiation of Phase 1 trial expected in 2H21 IND/CTA

EX-99.1 2 oric-20210810ex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update ORIC-101 on track for initial Phase 1b data readout in prostate cancer in 2H21 ORIC-533 IND cleared by FDA; initiation of Phase 1 trial expected in 2H21 IND/CTA filings for ORIC-944 and ORIC-114 expected in 2H21 Cash and investments of $305.9 million, expe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 8, 2021 ORIC Pharmaceuticals,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 8, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor ORIC expects to initiate single agent clinical trial in an undisclosed tumor type in 2H21 ORIC-533 IND fi

EX-99.1 2 d128943dex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor ORIC expects to initiate single agent clinical trial in an undisclosed tumor type in 2H21 ORIC-533 IND filing is the first of three IND/CTA filings expected in 2021 SOUTH SAN FRANCISCO and SAN DIEGO, CA – J

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 16, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuations ORIC-101 plasma concentrations provided excellent t

EX-99.1 2 d183984dex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel June 2, 2021 Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuatio

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission F

Form of Indenture

EX-4.2 2 d179648dex42.htm EX-4.2 Exhibit 4.2 ORIC PHARMACEUTICALS, INC. INDENTURE Dated as of [, 20] [], as Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable

Power of Attorney

Table of Contents As filed with the Securities and Exchange Commission on May 6, 2021.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission F

CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common stock, par value $0.0001 per share $ 150,000,000 $ 16,365 (1)

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255833 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common stock, par value $0.0001 per share $ 150,000,000 $ 16,365 (1) (1) The filing fee is calculated and being paid pursuant to Rule 457(r) under the Securities Act of 1933, as amend

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

Open Market Sale AgreementSM, dated May 6, 2021, by and between ORIC Pharmaceuticals, Inc. and Jefferies LLC

EX-1.1 2 d116190dex11.htm EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM May 6, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”),

ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021

EX-99.1 2 oric-ex9916.htm EX-99.1 EXHIBIT 99.1 ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 SOUTH SAN FRANCISCO and SAN DIEGO, CA – May 6, 2021 – ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage onco

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Definitive Proxy Statement

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

Form S-8

As filed with the Securities and Exchange Commission on March 23, 2021 Registration No.

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Lead program ORIC-101 on track for two initial data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 Cash, Cas

EX-99.1 2 oric-ex9917.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Lead program ORIC-101 on track for two initial data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 Cash, Cash Equivalents and Investments of $293.6 million expected to fund current operations into second half of

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 23, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissio

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P 109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated March 19, 2021, with respect to the ordinary shares of ORIC Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des

JOINT FILING AGREEMENT

EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021 Three IND/CTA f

EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 SOUTH SAN FRANCISCO and SAN DIEGO, CA – Jan. 11, 2021 – ORIC Pharmaceuticals

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 11, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Com

Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding

EX-99.2 Company Overview January 2021 Exhibit 99.2 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us” or “our”) future financial condition, results of

ORIC / Oric Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P 109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated November 18, 2020, with respect to the ordinary shares of ORIC Pharmaceuticals, Inc.

Oppenheimer & Co.

424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-250001 and 333-250053 Prospectus 5,040,000 shares Common stock We are offering 5,040,000 shares of our common stock to be sold in this offering. Our common stock is listed on the Nasdaq Global Select Market under the symbol “ORIC.” On November 12, 2020, the last reported sale price of our common stock on the Nasdaq Glob

- S-1MEF

S-1MEF As filed with the Securities and Exchange Commission on November 12, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ORIC PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 47-1787157 (State or other jurisdiction of incorporation or org

Power of Attorney (see page II-7 of the Registration Statement on Form S-1 (File No. 333-250001) filed on November 10, 2020).

S-1 Table of Contents As filed with the Securities and Exchange Commission on November 10, 2020.

Form of Underwriting Agreement, including Form of Lock-up Agreement.

EX-1.1 2 d94968dex11.htm EX-1.1 Exhibit 1.1 ORIC Pharmaceuticals, Inc. [●] Shares of Common Stock, par value $0.0001 per share Underwriting Agreement [●], 2020 J.P. Morgan Securities LLC Citigroup Global Markets Inc. Jefferies LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Citigroup Global Mark

-

CORRESP November 10, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Abby Adams Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-250001 Acceleration Request Requested Date: November 12, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentleme

-

CORRESP November 10, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

ORIC / Oric Pharmaceuticals, Inc. / Topspin Fund L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 68622P 109 (CUSIP Number) November 4, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2020 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss

Quarterly Report - 10Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update Expanded precision oncology pipeline through in-licensing of allosteric PRC2 inhibitor program and brain penetrant EGFR and HER2 exon 20 inhibitor program Lead program O

EX-99.1 2 oric-ex9917.htm EX-99.1 EXHIBIT 99.1 ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update Expanded precision oncology pipeline through in-licensing of allosteric PRC2 inhibitor program and brain penetrant EGFR and HER2 exon 20 inhibitor program Lead program ORIC-101 on track for multiple interim data readouts in 2021 Expect to file IND/CTAs for ORIC-533, ORIC-

ORIC-114 is a potential best-in-class inhibitor designed for brain penetrance and selectivity for exon 20 insertion mutations of EGFR and HER2 Initiation of global Phase 1/2 tumor-agnostic trial in genetically defined cancers expected in the second h

Exhibit 99.1 ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program ORIC-114 is a potential best-in-class inhibitor designed for brain penetrance and selectivity for exon 20 insertion mutations of EGFR and HER2 Initiation of global Phase 1/2 tumor-agnostic trial in genetically defined cancers expected in the second hal

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 19, 2020 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss

ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update Lead program ORIC-101 on track for multiple interim data readouts in 2021 and CD73 inhibitor ORIC-533 on track for IND filing in first half of 2021 Licensed exclusive w

Exhibit 99.1 ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update Lead program ORIC-101 on track for multiple interim data readouts in 2021 and CD73 inhibitor ORIC-533 on track for IND filing in first half of 2021 Licensed exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor; IND filing expected in second half of 2021

Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2020 ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics ORIC licenses exclusive worldwide development and commercialization rights to a potentia

EX-99.2 3 oric-ex99231.htm EX-99.2 Exhibit 99.2 ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics ORIC licenses exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor IND filing to support clinical development of ORIC-944 in prostate canc

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

Confidential Treatment Requested by ORIC Pharmaceuticals, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on July 20, 2020. This draft registration statement has not been publicly filed

Table of Contents Confidential Treatment Requested by ORIC Pharmaceuticals, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on July 20, 2020. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED S

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2020 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission

ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors

Exhibit 99.1 ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors SOUTH SAN FRANCISCO, CA – June 9, 2020 – ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Lori Kunkel, M.D., to its board of directors. Dr. Kunkel brings more than t

ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results Successful completion of $138.0 million initial public offering; cash and cash equivalents of $204.2 million as of April 30th expected to fund current operating plan in

Exhibit 99.1 ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results Successful completion of $138.0 million initial public offering; cash and cash equivalents of $204.2 million as of April 30th expected to fund current operating plan into 2023 Lead program ORIC-101 on track for multiple interim data readouts in 2021 and CD73 inhibitor ORIC-533 on track for IND filing in

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2020 ORIC Pharmaceuticals, Inc.

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated May 1, 2020, with respect to the ordinary shares of ORIC Pharmaceuticals, Inc.

ORIC / Oric Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P 109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address

ORIC / Oric Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) April 24, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

ORIC / Oric Pharmaceuticals, Inc. / Topspin Fund, L.P. - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 68622P 109 (CUSIP Number) April 23, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

JOINT FILING AGREEMENT

EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.

ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Exhibit 99.1 ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares South San Francisco, CA — April 28, 2020 — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the closing of its initial pu

Amended and Restated Bylaws of the Registrant.

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ORIC PHARMACEUTICALS, INC, (as amended and restated on March 26, 2020 and effective as of the closing of the Company's initial public offering) TABLE OF CONTENTS Page ARTICLE I—CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II—MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2020 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi

Amended and Restated Certificate of Incorporation

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ORIC PHARMACEUTICALS, INC. a Delaware corporation ORIC Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A.The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on August

Form S-8

S-8 As filed with the Securities and Exchange Commission on April 24, 2020 Registration No.

Dose Level 1A

424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-236792 and 333-237814 Prospectus 7,500,000 shares Common stock This is an initial public offering of shares of common stock by ORIC Pharmaceuticals, Inc. We are offering 7,500,000 shares of our common stock to be sold in the offering. The initial public offering price is $16.00 per share. Prior to this offering, there h

-

CORRESP Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O: 650.

Form S-1

S-1/A Table of Contents As filed with the Securities and Exchange Commission on April 23, 2020 Registration No.

Amended and Restated Certificate of Incorporation of the Registrant, as amended, as currently in effect.

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ORIC PHARMACEUTICALS, INC. ORIC Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is ORIC Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of t

- S-1MEF

S-1MEF As filed with the Securities and Exchange Commission on April 23, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ORIC PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 47-1787157 (State or other jurisdiction of incorporation or organi